Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.69 |
| ▸ | BCHE | P06276 | 7/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.67 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.65 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.63 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868549 | 1.00 | ACHE (0.69) | ACHEBCHEHRH3PABPC1EIF4H | |
| SCHEMBL29868444 | 0.88 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL5945373 | 0.88 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL29868453 | 0.88 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL5945321 | 0.88 | ACHE (0.85) | ACHEBCHE | |
| SCHEMBL8523409 | 0.83 | ACHE (0.81) | ACHEBCHEHRH3PABPC1EIF4H | |
| SCHEMBL8522924 | 0.83 | ACHE (0.77) | ACHEBCHEHRH3PABPC1EIF4H | |
| SCHEMBL5945394 | 0.83 | ACHE (0.77) | ACHEBCHEHRH3PABPC1EIF4H | |
| SCHEMBL15167949 | 0.82 | ACHE (1.00) | ACHEBCHEHRH3HRH2HRH1 | |
| SCHEMBL23106187 | 0.78 | BCHE (0.86) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4652054-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| JP-2006514922-A | — | — | 2006-05-18 | — | — | JP | claimed |
| EP-1558255-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Neuropharma, S.A. (ES) | 2005-08-03 | — | — | EP | claimed |
| WO-2004032929-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | NEUROPHARMA, S.A. (ES) | 2004-04-22 | — | — | WO | claimed |
| US-20060142323-A1 | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease | NEUROPHARMA, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
| EP-1558255-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Neuropharma, S.A. (ES) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004032929-A2 | DUAL BINDING SITE ACETYLCHOLINESTERASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | NEUROPHARMA, S.A. (ES) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142323-A1 | Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease | ACHE, PSEN2, CHAT | ACHE 1/4885BCHE 7/4885HRH3 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.